ArticleBone & joint open2026
Watchful waiting versus methylprednisolone or polidocanol injections as treatment of simple bone cysts.
Article in Bone & joint open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Simple bone cysts (SBCs) are among the most prevalent benign cystic bone lesions in children. The use of watchful waiting as management is debated, as are the type and timing of injection therapy. This study aims to compare clinical outcomes of watchful waiting and delayed and immediate percutaneous procedures in children with SBCs, together with the effectiveness of methylprednisolone and polidocanol. Methods: All eligible paediatric patients with SBCs and minimal one year of follow-up were included from our tertiary musculoskeletal oncology referral centre (January 2000 to December 2024). Outcomes of interest were cumulative incidence of (partial) healing (CI-Healing), cumulative incidence of failure (CI-Failure), and prognostic factors for healing and failure. For CI-Healing, competing risk analysis was performed with failure as the competing event. For CI-Healing and CI-Failure of methylprednisolone and polidocanol, landmark analysis was performed. Prognostic factors were estimated using a multivariate cause-specific hazard model. Results: In total, 160 paediatric patients with SBCs were included (mean age 8.7 years (SD 3.6); 128 (80%) males). Management consisted of watchful waiting (n = 41) and delayed (n = 86) or immediate (n = 33) percutaneous procedure. The median follow-up was 3.4 years (IQR 2.2 to 5.4). CI-Healing was significantly higher in immediate percutaneous procedures than in watchful waiting and delayed percutaneous procedures. Additionally, polidocanol performed significantly better than methylprednisolone regarding CI-Healing and CI-Failure. Lower limb localization was a significant negative prognostic factor for healing (cause-specific hazard ratio 0.38; 95% CI 0.18 to 0.82). Conclusion: For treatment of SBCs, watchful waiting showed high chances of necessitating subsequent treatment, leading to lower CI-Healing and prolonged exposure to risk of failure. If treatment is required, polidocanol is a superior injectable compared with methylprednisolone, in terms of both healing and failure prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.